Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 1701-1706, April 15, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dirven, H. A. A. M.
Right arrow Articles by van Bladeren, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dirven, H. A. A. M.
Right arrow Articles by van Bladeren, P. J.

The Role of Human Glutathione S-Transferase Isoenzymes in the Formation of Glutathione Conjugates of the Alkylating Cytostatic Drug Thiotepa1

Hubert A. A. M. Dirven2, Esther L. J. T. Dictus, Niek L. H. L. Broeders, Ben van Ommen3 and Peter J. van Bladeren

TNO Nutrition and Food Research Institute, Division of Toxicology, P.O. Box 360, 3700 AJ Zeist, the Netherlands

Nonenzymatic and glutathione S-transferase (GST) catalyzed glutathione (GSH) conjugation has been postulated as a mechanism by which alkylating cytostatic drugs can be inactivated intracellularly. In this study, we describe studies on the glutathione-dependent biotransformation of thiotepa (tris(1-aziridinyl)phosphine sulfide), a trifunctional alkylating agent.

31P NMR studies showed that thiotepa is stable in 0.07 M phosphate buffer, pH 7.4 (t1/2 = 3300 min). In the presence of glutathione, the rate of disappearance of thiotepa increased greatly (t1/2 = 282 min). Both monoglutathionyl thiotepa and diglutathionyl thiotepa conjugates were identified by 31P NMR and mass spectrometry. Addition of GST A1-1 ({alpha}) to an incubation of thiotepa and GSH further increased the rate of disappearance of thiotepa (t1/2 = 100 min) and increased the rate of formation of monoglutathionyl thiotepa. The rate of formation of diglutathionyl thiotepa was not altered, suggesting that the formation of diglutathionyl thiotepa is not catalyzed by GST A1-1.

The role of purified human GST on the formation of monoglutathionyl thiotepa was further studied by HPLC. In incubations with 0.2 mM thiotepa, 1 mM GSH, and 40 µM GST, both GST A1-1 and P1-1 enhanced the formation of the monoglutathionyl conjugate 30–35-fold above the nonenzymatic formation, while GST A2-2 and M1a-1a did not catalyze the rate of formation of this conjugate. Kms for the GST A1-1 ({alpha}) and P1-1 ({pi}) catalyzed formation of monoglutathionyl thiotepa were in the 5–7 mM range. Since the pH in tumors might be lower than in normal cells, the pH dependency of the GST P1-1 catalyzed formation of monoglutathionyl thiotepa was also studied. At all pHs tested (range, 5.5–8.5), a marked catalytic effect of both GST P1-1 and A1-1 on the formation of monoglutathionyl conjugates was noted.

The role of GST on the formation of monoglutathionyl conjugates of tepa (tris(1-aziridinyl)phosphine oxide), the major metabolite formed from thiotepa, was also studied. Both GST A1-1 and P1-1 could enhance the formation of the glutathione conjugate 37–46-fold above the spontaneous levels, while GST M1a-1a and A2-2 again did not increase the rate of formation of this conjugate. The results of these studies show that the aziridine moieties in thiotepa/tepa are substrates for both GST A1-1 and P1-1. Thus, GST catalyzed glutathione conjugation of thiotepa might be an important factor in the development of drug resistance towards thiotepa.

1 This study was supported by Grant TNOV-92-93 of the Dutch Cancer Society.

2 Present address: Nycomed Imaging, Department of Toxicology, Nycoveien 1-2, Oslo, Norway.

3 To whom requests for reprints should be addressed.

Received 11/ 8/94. Accepted 2/16/95.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Hohaus, A. Di Ruscio, A. Di Febo, G. Massini, F. D'Alo', F. Guidi, G. Mansueto, M. T. Voso, and G. Leone
Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma
Clin. Cancer Res., March 15, 2005; 11(6): 2175 - 2179.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Bennaceur-Griscelli, J. Bosq, S. Koscielny, F. Lefrere, A. Turhan, N. Brousse, O. Hermine, and V. Ribrag
High Level of Glutathione-S-Transferase {pi} Expression in Mantle Cell Lymphomas
Clin. Cancer Res., May 1, 2004; 10(9): 3029 - 3034.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. K. Smitherman, A. J. Townsend, T. E. Kute, and C. S. Morrow
Role of Multidrug Resistance Protein 2 (MRP2, ABCC2) in Alkylating Agent Detoxification: MRP2 Potentiates Glutathione S-Transferase A1-1-Mediated Resistance to Chlorambucil Cytotoxicity
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 260 - 267.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. K. Dasgupta, P. J. Adamson, F. E. Davies, S. Rollinson, P. L. Roddam, A. J. Ashcroft, A. M. Dring, J. A. L. Fenton, J. A. Child, J. M. Allan, et al.
Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma
Blood, October 1, 2003; 102(7): 2345 - 2350.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. M. Davies, L. L. Robison, J. D. Buckley, T. Tjoa, W. G. Woods, G. A. Radloff, J. A. Ross, and J. P. Perentesis
Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia
J. Clin. Oncol., March 1, 2001; 19(5): 1279 - 1287.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A.-S. Johansson, M. Ridderström, and B. Mannervik
The Human Glutathione Transferase P1-1 Specific Inhibitor TER 117 Designed for Overcoming Cytostatic-Drug Resistance Is also a Strong Inhibitor of Glyoxalase I
Mol. Pharmacol., March 1, 2000; 57(3): 619 - 624.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
H. Shiga, E. I. Heath, A. A. Rasmussen, B. Trock, P. G. Johnston, A. A. Forastiere, M. Langmacher, A. Baylor, M. Lee, and K. J. Cullen
Prognostic Value of p53, Glutathione S-Transferase {{pi}}, and Thymidylate Synthase for Neoadjuvant Cisplatin-based Chemotherapy in Head and Neck Cancer
Clin. Cancer Res., December 1, 1999; 5(12): 4097 - 4104.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. van Maanen, I. M. Tijhof, J. M. A. Damen, C. Versluis, J. J. K. van den Bosch, A. J. R. Heck, S. Rodenhuis, and J. H. Beijnen
A Search for New Metabolites of N,N',N''-Triethylenethiophosphoramide
Cancer Res., September 1, 1999; 59(18): 4720 - 4724.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. S. Morrow, P. K. Smitherman, S. K. Diah, E. Schneider, and A. J. Townsend
Coordinated Action of Glutathione S-Transferases (GSTs) and Multidrug Resistance Protein 1 (MRP1) in Antineoplastic Drug Detoxification. MECHANISM OF GST A1-1- AND MRP1-ASSOCIATED RESISTANCE TO CHLORAMBUCIL IN MCF7 BREAST CARCINOMA CELLS
J. Biol. Chem., August 7, 1998; 273(32): 20114 - 20120.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.